novobiocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 1974 | 303-81-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 40.81 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 4, 1964 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
| CHEBI has role | CHEBI:33281 | antibiotics |
| CHEBI has role | CHEBI:33282 | bactericides |
| CHEBI has role | CHEBI:50750 | inhibitors of type II topoisomerase |
| CHEBI has role | CHEBI:62868 | hepatoprotective agents |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Mastitis caused by Staphylococcus aureus | Indication |
| Cattle | Mastitis caused by Streptococcus agalactiae | Indication |
| Chickens | Treatment of staphylococcal synovitis | Indication |
| Chickens | Generalized staphylococcal infections | Indication |
| Chickens | Breast blisters associated with staphylococcal infections | Indication |
| Ducks | Infectious serositis | Indication |
| Ducks | Cholera caused by Pasteurella anatipestifer | Indication |
| Ducks | Cholera caused by Pasteurella multocida | Indication |
| Mustelids | Generalized infections caused by staphylococcal organisms | Indication |
| Mustelids | Abscesses caused by staphylococcal organisms | Indication |
| Mustelids | Urinary infections caused by staphylococcal organisms | Indication |
| Turkeys | Breast blisters associated with staphylococcal infections | Indication |
| Turkeys | Treatment of staphylococcal synovitis | Indication |
| Turkeys | Generalized staphylococcal infections | Indication |
| Turkeys | Cholera caused by Pasteurella multocida | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Albamix Feed Medication | Zoetis Inc. | 1 |
| Albacillin Suspension, Special Formula 17900-Forte Suspension | Zoetis Inc. | 2 |
| Albaplex 3x Tablets, Albaplex Tablets | Zoetis Inc. | 2 |
| Albadry Plus Suspension | Zoetis Inc. | 2 |
| Delta Albaplex 3x Tablets, Delta Albaplex Tablets | Zoetis Inc. | 3 |
| Albaplex Capsules | Zoetis Inc. | 2 |
| Albamast Suspension | Zoetis Inc. | 1 |
| Biodry Suspension, Drygard Suspension | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.33 | acidic |
| pKa2 | 8.95 | acidic |
| pKa3 | 10.13 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Microtubule-associated proteins 1A/1B light chain 3B | Unclassified | Kd | 4.76 | CHEMBL | |||||
| ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 4.18 | CHEMBL | |||||
| Microtubule-associated proteins 1A/1B light chain 3A | Unclassified | Kd | 5.12 | CHEMBL | |||||
| DNA gyrase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | IC50 | 6.81 | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | IC50 | 7.43 | CHEMBL | |||||
| ParE | Enzyme | IC50 | 5.69 | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | Kd | 7.55 | CHEMBL | |||||
| DNA gyrase | Enzyme | IC50 | 7 | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | IC50 | 6.70 | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | IC50 | 6.90 | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | IC50 | 7.34 | CHEMBL | |||||
| DNA gyrase subunit B | Enzyme | Ki | 8.15 | CHEMBL | |||||
| Genome polyprotein | Unclassified | IC50 | 4.85 | CHEMBL | |||||
| DNA topoisomerase 4 subunit B | Unclassified | IC50 | 5.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019861 | VUID |
| N0000147947 | NUI |
| D01209 | KEGG_DRUG |
| 4018076 | VANDF |
| 4019861 | VANDF |
| C0028458 | UMLSCUI |
| CHEBI:28368 | CHEBI |
| NOV | PDB_CHEM_ID |
| CHEMBL36506 | ChEMBL_ID |
| CHEMBL3183453 | ChEMBL_ID |
| D009675 | MESH_DESCRIPTOR_UI |
| DB01051 | DRUGBANK_ID |
| 12021 | IUPHAR_LIGAND_ID |
| 575 | INN_ID |
| 4309-70-0 | SECONDARY_CAS_RN |
| 1476-53-5 | SECONDARY_CAS_RN |
| 17EC19951N | UNII |
| 54675769 | PUBCHEM_CID |
| 215076 | RXNORM |
| 1436 | MMSL |
| 5193 | MMSL |
| d01116 | MMSL |
| 002761 | NDDF |
| 002762 | NDDF |
| 002763 | NDDF |
| 371187001 | SNOMEDCT_US |
| 65403003 | SNOMEDCT_US |
| 90220005 | SNOMEDCT_US |
| CHEMBL3544972 | ChEMBL_ID |
Pharmaceutical products:
None